Novartis AG (LON: 0K9E)

Market Cap	160.50B
Revenue (ttm)	37.26B
Net Income (ttm)	13.13B
Shares Out	n/a
EPS (ttm)	6.40
PE Ratio	12.22
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Mar 7, 2024

Volume	2,396
Average Volume	5,793
Open	99.13
Previous Close	98.46
Day's Range	98.72 - 99.18
52-Week Range	92.39 - 120.72
Beta	n/a
RSI	43.02
Earnings Date	Jan 31, 2025

About Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and ...

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 76,057
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K9E

Financial Performance

In 2023, Novartis AG's revenue was $46.66 billion, an increase of 7.36% compared to the previous year's $43.46 billion. Earnings were $14.85 billion, an increase of 113.52%.

Financial numbers in USD